Demolish Delhi Jama Masjid, hang me if idols are not found: Sakshi Maharaj

Bengaluru, May 21: The top two food-delivery startups, Swiggy and Zomato, will begin delivering alcohol in some cities starting from today, as they cash in on the high demand for booze during the country's coronavirus lockdown.

India was among the few countries to restrict liquor and tobacco sales as it announced one of the world's strictest lockdowns in March.

Hundreds of people started queuing up at liquor stores earlier this month when the government eased some restrictions, leading the police to resort to baton-charges to disperse crowds in some cases.

The companies will roll out the service in select cities in Jharkhand, starting with Ranchi from today, Swiggy and Zomato said in separate statements.

Swiggy said it was in advanced talks with multiple states to launch the service in more locations, and both firms said the move to allow alcohol orders through smartphones will promote social distancing and customer safety.

"By enabling home delivery of alcohol, we can generate additional business for retail outlets while solving the problem of overcrowding," said Anuj Rathi, vice president of products at Bengaluru-based Swiggy.

The new service also comes as both Swiggy and Zomato face sharp declines in their core business, with restaurants remaining shut during the two-month lockdown, forcing the companies to cut hundreds of jobs to save cash.

News agency reported earlier this month that Zomato was aiming to branch out into delivering alcohol. Swiggy is backed by South African internet group Naspers Ltd, while Ant Financial, an affiliate of Chinese e-commerce giant Alibaba Group Holding Ltd, is a major investor in Zomato.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.